The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 36 | — | 20.1x | Near average | |
Growth | 90 | 611.0% | 5.6% | Above average | |
Quality | 38 | -373.6% | 7.6% | Near average | |
Safety | 39 | 3.0x | 0.4x | Near average | |
Capital Return | 76 | — | 2.19% | Above average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
BioAge Labs, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy BioAge Labs, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The target forecasts for BioAge stock saw a slight decrease in the Consensus by 3.54% over the past thirty days, dropping from 42.2 to 43.75 dollars, coinciding with one analyst exiting the coverage range. Despite this slight adjustment, there remains a sharp Dispersion in the estimates of the six current analysts, with forecasts ranging from a low of 23 dollars to a very optimistic high of 62 dollars, reflecting a state of uncertainty regarding fair valuation despite the consensus 'Buy' rating.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.